| 14.46 0 (0%) | 04-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 16.91 | 1-year : | 19.75 |
| Resists | First : | 14.47 | Second : | 16.91 |
| Pivot price | 14.44  |
|||
| Supports | First : | 14.39 |
Second : | 14.34 |
| MAs | MA(5) : | 14.46  |
MA(20) : | 14.43 |
| MA(100) : | 13.39 |
MA(250) : | 9.66 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 78.1 |
D(3) : | 82.1 |
| RSI | RSI(14): 66.3 | |||
| 52-week | High : | 14.47 | Low : | 5.51 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ FOLD ] has closed below upper band by 31.0%. Bollinger Bands are 93.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 63 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.5 - 14.57 | 14.57 - 14.63 |
| Low: | 14.25 - 14.35 | 14.35 - 14.43 |
| Close: | 14.32 - 14.47 | 14.47 - 14.59 |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Fri, 10 Apr 2026
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Tue, 07 Apr 2026
Amicus Therapeutics stock hits 52-week high at 14.46 USD - Investing.com
Tue, 07 Apr 2026
Amicus Therapeutics (NASDAQ:FOLD) Hits New 1-Year High - Time to Buy? - MarketBeat
Mon, 06 Apr 2026
Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Tue, 31 Mar 2026
Amicus Therapeutics stock hits 52-week high at $14.44 - Investing.com
Sun, 29 Mar 2026
210,800 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by CIBRA Capital Ltd - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 314 (M) |
| Shares Float | 311 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 104.1 (%) |
| Shares Short | 20,190 (K) |
| Shares Short P.Month | 17,640 (K) |
| EPS | -0.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.87 |
| Profit Margin | -4.3 % |
| Operating Margin | 8.6 % |
| Return on Assets (ttm) | 2.4 % |
| Return on Equity (ttm) | -11.6 % |
| Qtrly Rev. Growth | 23.7 % |
| Gross Profit (p.s.) | 1.78 |
| Sales Per Share | 2.01 |
| EBITDA (p.s.) | 0.13 |
| Qtrly Earnings Growth | -95.5 % |
| Operating Cash Flow | 33 (M) |
| Levered Free Cash Flow | 48 (M) |
| PE Ratio | -160.67 |
| PEG Ratio | 0 |
| Price to Book value | 16.43 |
| Price to Sales | 7.15 |
| Price to Cash Flow | 136.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|